Page last updated: 2024-12-06

tetrahydro-11-deoxycortisol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tetrahydro-11-deoxycortisol (THDOC) is a steroid hormone that is a precursor to cortisol. It is produced in the adrenal glands and is involved in the regulation of blood sugar levels. THDOC is also a potent anti-inflammatory agent. THDOC is studied because it is a marker of cortisol production and may be useful in the diagnosis and treatment of adrenal disorders. It is also of interest as a potential therapeutic agent for inflammatory diseases.'

tetrahydro-11-deoxycortisol: (3alpha,5beta)-isomer has angiostatic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65555
CHEBI ID34352
SCHEMBL ID3449603
MeSH IDM0054089

Synonyms (29)

Synonym
nsc-53901
nsc53901
68-60-0
3alpha,17alpha,21-trihydroxy-5beta-pregnan-20-one
tetrahydro-11-deoxycortisol
5beta-pregnane-3alpha,17alpha,21-triol-20-one
1-[(3r,5r,8r,9s,10s,13s,14s,17r)-3,17-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-hydroxyethanone
LMST05030014
tetrahydrodeoxycortisol
trihydroxypregnanone
tetrahydro compound s
3alpha,17,21-trihydroxy-5beta-pregnan-20-one
nsc 53901
einecs 200-691-0
pregnan-20-one, 3,17,21-trihydroxy-, (3alpha,5beta)-
tetrahydro-reichstein's substance s
tetrahydro-s
tetrahydrocortexolone
tetrahydro-11-deoxy cortisol
11-deoxytetrahydrocortisol
SCHEMBL3449603
CHEBI:34352
3-naphthalen-1-yl-quinoxaline-5-carboxylicacid
Q27116008
DTXSID001018945
pregnan-20-one, 3,17,21-trihydroxy-, (3a,5b)-
HY-113423
CS-0059446
AKOS040755282
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
21-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (34.69)18.7374
1990's17 (34.69)18.2507
2000's10 (20.41)29.6817
2010's5 (10.20)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.27 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.92%)5.53%
Reviews4 (7.84%)6.00%
Case Studies2 (3.92%)4.05%
Observational0 (0.00%)0.25%
Other43 (84.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]